NCT06050941 is a Phase 2 clinical trial of idarubicin in Acute Myeloid Leukemia, sponsored by First Affiliated Hospital of Zhejiang University.

Who is sponsoring NCT06050941?

NCT06050941 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT06050941?

Interventions in NCT06050941: idarubicin, Cytarabine.

What condition does NCT06050941 study?

NCT06050941 studies Acute Myeloid Leukemia, Myelodysplastic Syndromes.

Is NCT06050941 still recruiting?

NCT06050941 is currently not yet recruiting. Last updated 5 March 2024.

Last reviewed 2024-03-05 · How we verify

NCT06050941

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Not yet recruiting Phase 2 Last updated 5 March 2024

What this trial tests

Phase 2 trial testing idarubicin in Acute Myeloid Leukemia in 60 participants. Not yet recruiting.

Timeline

2 April 2024

Primary endpoint
2 April 2026

2 April 2027

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	2 April 2024
Primary completion	2 April 2026
Estimated completion	2 April 2027

Drugs / interventions tested

idarubicin (IDARUBICIN) — full drug profile →
Cytarabine — full drug profile →

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Adults 18 to 60, any sex, with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Reduced intensive 3 + 5 idarubicin and cytarabine chemotherapy plus venetoclax as first-line treatment for adults with acute myeloid leukaemia and high-risk myelodysplastic syndrome

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries.
Morcos-Sandino M, Quezada-Ramírez SI, Gómez-De León A. · · 2025 · cited 1× · PMID 40427048 · DOI 10.3390/biomedicines13051221

Verify or expand the search:

Other trials of idarubicin

Trials testing the same drug.

NCT06744504 — Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 · Phase 3 · recruiting
NCT03661515 — Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML · Phase 1 · completed
NCT02632708 — Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diag · Phase 1 · active not recruiting
NCT01876953 — Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia · Phase 1, PHASE2 · terminated
NCT00534469 — Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R · Phase 2 · completed

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06050941 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 5 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06050941.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing